Veracyte Inc 2025年季度报告

Table of Contents Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐Nox As of May2, 2025, there were78,314,611shares of common stock, par value $0.001 per share, outstanding. PARTI. — FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance Sheets as ofMarch31, 2025and December31, 2024Condensed Consolidated Statements of Operations for the ThreeMonth Periods EndedMarch31, 2025and 2024Condensed Consolidated Statements of Comprehensive Income (Loss) for the ThreeMonthPeriods EndedMarch31, 2025and 2024Condensed Consolidated Statements of Stockholders' Equity for the ThreeMonth PeriodsEndedMarch31, 2025and 2024Condensed Consolidated Statements of Cash Flows for theThreeMonth Periods EndedMarch31, 2025and 2024Notes to Condensed Consolidated Financial StatementsItem 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPARTII. — OTHER INFORMATIONItem 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Defaults Upon Senior SecuritiesItem 4. Mine Safety DisclosuresItem 5. Other InformationItem 6. ExhibitsSIGNATURES VERACYTE,INC. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or this report, contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. All statements contained in this report other than statements of historical fact, including statements In some cases, you can identify forward-looking statements by such terminology as “believe,” “may,” “will,” “potentially,” “expect,”“estimate,” “continue,” “ongoing,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that conveyuncertainty of future events or outcomes, although not all forward-looking statements contain these words. These are statements that relate •the factors that may impact our financial results;•our expectations regarding total revenue and total test volume;•our expectations with respect to our future research and development, general and administrative and selling and marketingexpenses and our anticipated uses of our funds;•the impact of inflation, volatile interest rates and foreign exchange fluctuations, as well as regional conflicts globally, including thewar in Ukraine, the ongoing conflict in the Middle East, any impacts of the new administration, energy, trade and supply chaindisruptions, and market volatility resulting from the above on our business;•the effects of evolving international trade policies and government actions relating to tariffs;•our beliefs with respect to importance of maintaining libraries of clinical evidence;•our expectations regarding the Percepta Nasal Swab classifier for early lung cancer classification and the Prosigna breast cancerassay;•our expectations regarding the addition of minimal residual detection capabilities to our diagnostics platform;•our expectations regarding the timing and success of our transition to offering more of our tests as in vitro diagnostic tests onmultiple platforms worldwide;•our ability to continue to receive quality reagents and other raw materials from certain single source suppliers, and to manufactureour in vitro diagnostics, or IVD, products;•our ability to successfully integrate C2i Genomics, Inc., or C2i, HalioDx and Decipher Biosciences into our business and ourability to develop and launch tests, and enter into supply agreements, with manufacturers of alternative systems;•our expectations regarding our partnerships and agreements; We caution you that the foregoing list does not contain all of the forward-looking statements made in this report. We have based theseforward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect ourbusiness, financial condition, results of operations, prospects, and financial needs. These forward-looking statements speak only as of thedate of this report and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” in Part II,Item 1A and elsewhere in this report and in the section titled “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K f